Sage Journals: Discover world-class research

Abstract

This article reports a case of probable hepatotoxicity induced by therapeutic doses of labetalol. A 34-year-old postpartum woman was started on labetalol during a preeclamptic episode in the hospital. During the patient's 4-week postpartum office visit, she reported having dark urine for the previous 2 weeks. A liver function test showed substantial enzyme elevation, which improved after discontinuation of labetalol therapy. Labetalol-induced hepatotoxicity, although uncommon, can occur. Published data report this occurrence only in middle-aged or older patients. This appears to be the first case report of postpartum labetalol-induced hepatotoxicity. Hepatotoxicity may occur as a result of labetalol therapy. More judicious monitoring in patients on labetalol therapy may be warranted to prevent serious outcomes.

Keywords

Labetalol hepatotoxicity postpartum.

Get full access to this article

View all access options for this article.

References

Lunell NO , Nylund L. , Lewander R. , Sarby B. Acute effect of an antihypertensive drug, labetalol, on uteroplacental blood flow. Br J Obstet Gynaecol. 1982;89:640-644.

Lunell NO , Fredholm B. , Hjemdahl P. , et al. Labetalol, a combined alpha- and beta-blocker, in hypertension pregnancy. Acta Med Scand Suppl. 1982;665:143-147.

Michelson EL , Frishman WH , Lewis JE , et al. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension. Am J Med. 1983;75(suppl 4A): 68-80.

Douglas DD , Yang RD , Jensen P. , Thiele DL Fatal labetalol-induced hepatic injury. Am J Med. 1989;87:235-236.

Stumpf JL Fatal hepatotoxicity induced by hydralazine or labetalol. Pharmacotherapy. 1991;11:415-418.

Clark JA , Zimmerman HJ , Tanner LA Labetalol hepatotoxicity. Ann Int Med. 1990 ;113:210-213.

Naranjo CA , Busto U. , Sellers EM , et al. A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther. 1981;30:239-245.

Jacqz E. , Hall SD , Branch RA Genetically determined polymorphisms in drug oxidations. Hepatology. 1986;6:1020-1032.

Teoh NC , Farrell GC Liver Disease Caused by Drugs in Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management 8th ed. Philadelphia, PA: Saunders Elsevier; 2006:1807-1852.

10.

Lee WM Drug-induced hepatotoxicity. N Engl J Med. 2003; 349:474-485.

11.

Kelly BD , Heneghan MA , Bennani F. , Connolly CE , O'Gorman TA. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells . Am J Gastroenterol. 1998;93:819-821.

12.

Karpman E. , Kurzrock EA Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol. 2004;172:448-453.

13.

Sharp JR , Ishak KG , Zimmerman HJ Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin . Ann Intern Med. 1980;92:4-19.

14.

Sibai BM Hypertension in Obstetrics: Normal and Problem Pregnancies. 4th ed. Philadelphia, PA: Harcourt Health Sciences Company; 2002:957-972.

15.

Martin JN Jr, Blake PG , Perry KG Jr, McCaul JF , Hess LW , Martin RW The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol. 1991;164:1500.

16.

Drugdex System. Thomson Micromedex. Greenwood Village, CO.

17.

Schroeder BM ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. Am Fam Physician. 2002;66:330.

Probable Labetalol-Induced Hepatotoxicity

Abstract

Keywords

Get full access to this article

References